| Literature DB >> 29977454 |
Ning Li1, Ling Li2, Yongshun Chen3.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies, which causes serious financial burden worldwide. This study aims to investigate the potential mechanisms contributing to HCC and identify core biomarkers. The HCC gene expression profile GSE41804 was picked out to analyze the differentially expressed genes (DEGs). Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were carried out using DAVID. We constructed a protein-protein interaction (PPI) network to visualize interactions of the DEGs. The survival analysis of these hub genes was conducted to evaluate their potential effects on HCC. In this analysis, 503 DEGs were captured (360 downregulated genes and 143 upregulated genes). Meanwhile, 15 hub genes were identified. GO analysis showed that the DEGs were mainly enriched in oxidative stress, cell cycle, and extracellular structure. KEGG analysis suggested the DEGs were enriched in the absorption, metabolism, and cell cycle pathway. PPI network disclosed that the top3 modules were mainly enriched in cell cycle, oxidative stress, and liver detoxification. In conclusion, our analysis uncovered that the alterations of oxidative stress and cell cycle are two major signatures of HCC. TOP2A, CCNB1, and KIF4A might promote the development of HCC, especially in proliferation and differentiation, which could be novel biomarkers and targets for diagnosis and treatment of HCC.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29977454 PMCID: PMC5994271 DOI: 10.1155/2018/3478305
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1(a) Heat map of 50 representative DEGs. (b) Volcano plot of genes detected in HCC. Red means upregulated DEGs; green means downregulated DEGs; blue means no difference.
Top 15 hub genes with higher degree of connectivity.
| Gene | Degree of connectivity | Adjusted |
|---|---|---|
| TOP2A | 48 | 2.13 |
| CDK1 | 43 | 1.87 |
| CCNB1 | 42 | 3.57 |
| BUB1 | 42 | 1.31 |
| CENPF | 41 | 2.23 |
| CCNB2 | 40 | 3.11 |
| TTK | 40 | 1.06 |
| KIF2C | 40 | 5.80 |
| HMMR | 40 | 2.10 |
| MELK | 40 | 9.21 |
| CENPE | 39 | 2.49 |
| KIF20A | 39 | 1.33 |
| KIF4A | 39 | 4.66 |
| PBK | 39 | 1.07 |
| DLGAP5 | 39 | 1.01 |
Gene ontology analysis of differentially expressed genes associated with hepatocellular carcinoma.
| Expression | Category | Term | Count | % |
| FDR |
|---|---|---|---|---|---|---|
| Downregulated | GOTERM_BP_DIRECT | GO:0019373~epoxygenase P450 pathway | 7 | 0.02 | 5.20 | 8.49 |
| GOTERM_BP_DIRECT | GO:0055114~oxidation-reduction process | 26 | 0.09 | 7.31 | 1.19 | |
| GOTERM_BP_DIRECT | GO:0071294~cellular response to zinc ion | 7 | 0.02 | 7.53 | 1.23 | |
| GOTERM_BP_DIRECT | GO:0045926~negative regulation of growth | 7 | 0.02 | 7.53 | 1.23 | |
| GOTERM_BP_DIRECT | GO:0042738~exogenous drug catabolic process | 6 | 0.02 | 1.95 | 3.19 | |
| GOTERM_CC_DIRECT | GO:0005576~extracellular region | 54 | 0.18 | 2.46 | 3.08 | |
| GOTERM_CC_DIRECT | GO:0005615~extracellular space | 44 | 0.14 | 1.19 | 1.49 | |
| GOTERM_CC_DIRECT | GO:0031090~organelle membrane | 12 | 0.04 | 5.53 | 6.91 | |
| GOTERM_CC_DIRECT | GO:0005887~integral component of plasma membrane | 41 | 0.14 | 1.42 | 1.77 | |
| GOTERM_CC_DIRECT | GO:0016323~basolateral plasma membrane | 12 | 0.04 | 9.02 | 0.01 | |
| GOTERM_MF_DIRECT | GO:0016705~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 10 | 0.03 | 2.41 | 3.42 | |
| GOTERM_MF_DIRECT | GO:0019825~oxygen binding | 9 | 0.03 | 8.01 | 1.14 | |
| GOTERM_MF_DIRECT | GO:0005506~iron ion binding | 13 | 0.04 | 3.31 | 4.70 | |
| GOTERM_MF_DIRECT | GO:0004497~monooxygenase activity | 9 | 0.03 | 4.36 | 6.19 | |
| GOTERM_MF_DIRECT | GO:0016712~oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 6 | 0.02 | 6.52 | 9.26 | |
|
| ||||||
| Upregulated | GOTERM_BP_DIRECT | GO:0007067~mitotic nuclear division | 19 | 16.67 | 5.25 | 7.80 |
| GOTERM_BP_DIRECT | GO:0051301~cell division | 19 | 16.67 | 1.94 | 2.90 | |
| GOTERM_BP_DIRECT | GO:0007062~sister chromatid cohesion | 12 | 10.53 | 2.16 | 3.23 | |
| GOTERM_BP_DIRECT | GO:0007059~chromosome segregation | 8 | 7.02 | 1.44 | 2.16 | |
| GOTERM_BP_DIRECT | GO:0034501~protein localization to kinetochore | 4 | 3.51 | 2.31 | 0.03 | |
| GOTERM_CC_DIRECT | GO:0030496~midbody | 10 | 0.06 | 2.85 | 3.40 | |
| GOTERM_CC_DIRECT | GO:0000776~kinetochore | 8 | 0.05 | 2.45 | 2.93 | |
| GOTERM_CC_DIRECT | GO:0000777~condensed chromosome kinetochore | 7 | 0.04 | 6.94 | 0.01 | |
| GOTERM_CC_DIRECT | GO:0000775~chromosome, centromeric region | 6 | 0.03 | 1.29 | 0.02 | |
| GOTERM_CC_DIRECT | GO:0005871~kinesin complex | 5 | 0.03 | 1.81 | 0.22 | |
| GOTERM_MF_DIRECT | GO:0005515~protein binding | 72 | 63.16 | 4.54 | 0.01 | |
| GOTERM_MF_DIRECT | GO:0003777~microtubule motor activity | 5 | 4.39 | 0.001073553 | 1.34 | |
| GOTERM_MF_DIRECT | GO:0008017~microtubule binding | 6 | 5.26 | 0.006401849 | 7.77 | |
| GOTERM_MF_DIRECT | GO:0003682~chromatin binding | 8 | 7.02 | 0.006540341 | 7.93 | |
| GOTERM_MF_DIRECT | GO:0004693~cyclin-dependent protein serine/threonine kinase activity | 3 | 2.63 | 0.015639967 | 18.01 | |
GO: gene ontology; FDR: false discovery rate.
KEGG pathway analysis of differentially expressed genes associated with hepatocellular carcinoma.
| Category | Term | Count | % |
| Genes | FDR |
|---|---|---|---|---|---|---|
| Downregulated DEGs | hsa04978: mineral absorption | 9 | 0.03 | 2.22 | MT1M, SLC5A1, MT2A, MT1E, TRPV6, MT1H, MT1X, MT1G, and MT1F | 2.68 |
| hsa00830: retinol metabolism | 10 | 0.03 | 2.90 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, ADH4, ADH1B, CYP26A1, CYP2A6, CYP1A2, and RDH16 | 3.50 | |
| hsa00232: caffeine metabolism | 4 | 0.01 | 2.79 | XDH, NAT2, CYP2A6, and CYP1A2 | 0.03 | |
| hsa00982: drug metabolism-cytochrome P450 | 8 | 0.03 | 4.75 | CYP3A4, CYP2B6, CYP2C8, ADH4, ADH1B, CYP2A6, CYP2E1, and CYP1A2 | 0.06 | |
| hsa05204: chemical carcinogenesis | 8 | 0.03 | 1.35 | CYP3A4, CYP2C8, ADH4, NAT2, ADH1B, CYP2A6, CYP2E1, and CYP1A2 | 0.16 | |
|
| ||||||
| Upregulated DEGs | hsa04110: cell cycle | 8 | 0.05 | 9.30 | CCNB1, CDK1, CCNB2, BUB1, TTK, PTTG1, SFN, and CDC25C | 9.18 |
| hsa04115: p53 signaling pathway | 6 | 0.04 | 1.03 | CCNB1, CDK1, CCNB2, RRM2, SFN, and GTSE1 | 0.01 | |
| hsa04914: progesterone-mediated oocyte maturation | 5 | 0.03 | 5.69 | CCNB1, CDK1, CCNB2, BUB1, and CDC25C | 0.56 | |
| hsa04114: oocyte meiosis | 4 | 0.03 | 0.01 | CDK1, BUB1, PTTG1, and CDC25C | 11.64 | |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: false discovery rate.
Figure 2(a) GO analysis of downregulated DEGs. (b) GO analysis of upregulated DEGs. (c) KEGG pathway of DEGs. (d) The protein-protein interaction (PPI) network of the top 15 hub genes.
Figure 3Top 3 modules from the protein-protein interaction network: (a) module 1, (b) module 2, and (c) module 3.
The enriched pathways of top 3 modules.
| Module | Term |
| FDR | Genes |
|---|---|---|---|---|
| Module 1 | Cell cycle | 2.66 | 1.96 | CCNB1, CDK1, CCNB2, BUB1, TTK, PTTG1, and CDC25C |
| ATP binding | 3.86 | 3.59 | CDK1, KIF4A, NEK2, KIF18B, TTK, CENPE, PBK, KIF2C, BUB1, TOP2A, MELK, TRIP13, and KIF20A | |
| Kinesin, motor region, and conserved site | 1.54 | 0.0016579 | KIF2C, KIF4A, KIF18B, CENPE, and KIF20A | |
| Kinesin, motor domain | 2.30 | 0.00247205 | KIF2C, KIF4A, KIF18B, CENPE, and KIF20A | |
| p53 signaling pathway | 3.59 | 0.002649002 | CCNB1, CDK1, CCNB2, RRM2, and GTSE1 | |
|
| ||||
| Module 2 | Cytochrome P450, conserved site | 4.98 | 3.11 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, CYP26A1, CYP2A6, and CYP1A2 |
| Cytochrome P450 | 9.23 | 5.74 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, CYP26A1, CYP2A6, and CYP1A2 | |
| Monooxygenase | 3.58 | 2.84 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, CYP26A1, CYP2A6, and CYP1A2 | |
| Organelle membrane | 6.92 | 3.79 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, CYP26A1, CYP2A6, and CYP1A2 | |
| Metal ion-binding site: iron (heme axial ligand) | 8.64 | 6.13 | CYP3A4, CYP4A11, CYP2B6, CYP2C8, CYP26A1, CYP2A6, and CYP1A2 | |
|
| ||||
| Module 3 | Metal-thiolate cluster | 2.15 | 1.80 | MT1M, MT2A, MT1E, MT1H, MT1G, MT1X, MT1F |
| Metallothionein, vertebrate, and metal binding site | 2.35 | 1.91 | MT1M, MT2A, MT1E, MT1H, MT1G, MT1X, and MT1F | |
| Metallothionein, vertebrate | 5.17 | 4.19 | MT1M, MT2A, MT1E, MT1H, MT1G, MT1X, and MT1F | |
| Metallothionein domain | 5.17 | 4.19 | MT1M, MT2A, MT1E, MT1H, MT1G, MT1X, and MT1F | |
| Metallothionein superfamily, eukaryotic | 5.17 | 4.19 | MT1M, MT2A, MT1E, MT1H, MT1G, MT1X, and MT1F | |
Figure 4Prognostic value of 15 genes ((a) TOP2A, (b) CDK1, (c) CCNB1, (d) BUB1, (e) CENPF, (f) CCNB2, (g) TTK, (h) KIF2C, (i) HMMR, (j) MELK, (k) CENPE, (l) KIF20A, (m) KIF4A, (n) PBK, and (o) DLGAP5) in HCC. P < 0.05 was regarded statistically different.
KEGG pathway analysis of top 15 hub genes with higher degree of connectivity.
| Term | Count | % |
| Genes | FDR |
|---|---|---|---|---|---|
| cfa04110: cell cycle | 5 | 0.18 | 5.08 | CCNB1, CDK1, CCNB2, BUB1, and TTK | 3.05 |
| cfa04914: progesterone-mediated oocyte maturation | 4 | 0.15 | 1.93 | CCNB1, CDK1, CCNB2, and BUB1 | 0.01 |
| cfa04115: p53 signaling pathway | 3 | 0.11 | 8.88 | CCNB1, CDK1, and CCNB2 | 0.53 |
| cfa04114: oocyte meiosis | 2 | 0.07 | 0.07 | CDK1, BUB1 | 37.98 |
| cfa04068: FoxO signaling pathway | 2 | 0.07 | 0.09 | CCNB1, CCNB2 | 44.34 |
KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: false discovery rate.
Figure 5(a–d) Expression level of TOP2A, CCNB1, KIF4A, and CCNB2 in HCC and normal tissues. Number (T = 369, N = 160); ∗P < 0.05. (e) TOP2A, CCNB1, and KIF4A protein were strongly upregulated in HCC tissues compared with normal liver tissues based on The Human Protein Atlas database. The normal liver tissue of TOP2A was from a female, aged 32, (patient ID: 1846; staining: not detected; intensity: negative; quantity: negative; location: none), and the HCC tissue was from a male, aged 80 (patient ID: 2280; staining: low; intensity: moderate; quantity: <25%; location: cytoplasmic/membranous nuclear). The normal liver tissue of CCNB1 was from a female, ages 63, (patient ID: 3222; staining: not detected; intensity: negative; quantity: negative; location: none), and the HCC tissue was from a female, aged 41, (patient ID: 5037; staining: moderate; intensity: weak; quantity: <25%; location: cytoplasmic/membranous nuclear). The normal liver tissue of KIF4A was from a female, aged 54 (patient ID: 3402; staining: not detected; intensity: negative; quantity: negative; location: none), and the HCC tissue was from a male, aged 67, (patient ID: 3477; staining: moderate; intensity: moderate; quantity: >75%; location: cytoplasmic/membranous nuclear). (f) The correlation analysis between CCNB1 and CDK1. CCNB1 and CDK1 are obviously positively correlated.
Figure 6Gene set enrichment analysis (GSEA). Listed pictures are 10 representative functional gene sets enriched in HCC with CCNB2 highly expressed.
Figure 7Reidentification of oxidative stress in HCC. (a) SOD activity, MDA production, and GSH-Px activity in the indicated group (n = 6). (b) The mRNA levels of NADPH P67 and gp91. (n = 6). (c, d) Western blotting analysis and quantitative data of oxidative stress (n = 6). (e) Representative images of immunohistochemical staining for the 4-HNE protein. ∗P < 0.05 versus Adj. group. Adj: adjacent tissue; HCC: hepatocellular carcinoma.